カテゴリー： Market Monitor Global, 世界, 医療/バイオ

眼咽頭型筋ジストロフィー（OPMD）の世界市場見通し2023年-2029年

◆英語タイトル：Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5821）◆商品コード：MMG23JU5821
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：79
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Oculopharyngeal Muscular Dystrophy (OPMD) Market 調査レポートは次の情報を含め、グローバルにおけるの眼咽頭型筋ジストロフィー（OPMD）市場規模と予測を収録しています。・世界の眼咽頭型筋ジストロフィー（OPMD）市場：売上、2018年-2023年、2024年-2029年
・世界の眼咽頭型筋ジストロフィー（OPMD）市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の眼咽頭型筋ジストロフィー（OPMD）市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「錠剤」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

眼咽頭型筋ジストロフィー（OPMD）のグローバル主要企業は、Benitec Biopharma Inc.、 Bioblast Pharma、 BioMarin、 PTC Therapeutics、 NS Pharma、 Nobelpharma Co., Ltd、 Santhera Pharmaceuticals、 Pfizer Inc.、 Marathon Pharmaceuticals、 Fibrogen、 Bristol-Myers Squibb、 Sarepta Therapeutics、 GSKなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、眼咽頭型筋ジストロフィー（OPMD）のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の眼咽頭型筋ジストロフィー（OPMD）市場：タイプ別、2018年-2023年、2024年-2029年
世界の眼咽頭型筋ジストロフィー（OPMD）市場：タイプ別市場シェア、2022年
・錠剤、カプセル、注射剤、その他

世界の眼咽頭型筋ジストロフィー（OPMD）市場：用途別、2018年-2023年、2024年-2029年
世界の眼咽頭型筋ジストロフィー（OPMD）市場：用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン薬局

世界の眼咽頭型筋ジストロフィー（OPMD）市場：地域・国別、2018年-2023年、2024年-2029年
世界の眼咽頭型筋ジストロフィー（OPMD）市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における眼咽頭型筋ジストロフィー（OPMD）のグローバル売上、2018年-2023年
・主要企業における眼咽頭型筋ジストロフィー（OPMD）のグローバル売上シェア、2022年
・主要企業における眼咽頭型筋ジストロフィー（OPMD）のグローバル販売量、2018年-2023年
・主要企業における眼咽頭型筋ジストロフィー（OPMD）のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Benitec Biopharma Inc.、 Bioblast Pharma、 BioMarin、 PTC Therapeutics、 NS Pharma、 Nobelpharma Co., Ltd、 Santhera Pharmaceuticals、 Pfizer Inc.、 Marathon Pharmaceuticals、 Fibrogen、 Bristol-Myers Squibb、 Sarepta Therapeutics、 GSK

*************************************************************

・調査・分析レポートの概要
眼咽頭型筋ジストロフィー（OPMD）市場の定義
市場セグメント
世界の眼咽頭型筋ジストロフィー（OPMD）市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の眼咽頭型筋ジストロフィー（OPMD）市場規模
世界の眼咽頭型筋ジストロフィー（OPMD）市場規模：2022年 VS 2029年
世界の眼咽頭型筋ジストロフィー（OPMD）市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの眼咽頭型筋ジストロフィー（OPMD）の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の眼咽頭型筋ジストロフィー（OPMD）製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：錠剤、カプセル、注射剤、その他
眼咽頭型筋ジストロフィー（OPMD）のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、オンライン薬局
眼咽頭型筋ジストロフィー（OPMD）の用途別グローバル売上・予測

・地域別市場分析
地域別眼咽頭型筋ジストロフィー（OPMD）市場規模 2022年と2029年
地域別眼咽頭型筋ジストロフィー（OPMD）売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Benitec Biopharma Inc.、 Bioblast Pharma、 BioMarin、 PTC Therapeutics、 NS Pharma、 Nobelpharma Co., Ltd、 Santhera Pharmaceuticals、 Pfizer Inc.、 Marathon Pharmaceuticals、 Fibrogen、 Bristol-Myers Squibb、 Sarepta Therapeutics、 GSK
...

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
This report aims to provide a comprehensive presentation of the global market for Oculopharyngeal Muscular Dystrophy (OPMD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oculopharyngeal Muscular Dystrophy (OPMD). This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2022 (%)
The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Tablets Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, by Type, 2022 (%)
Tablets
Capsules
Injectable
Other
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2022 (%)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oculopharyngeal Muscular Dystrophy (OPMD), market overview.
Chapter 2: Global Oculopharyngeal Muscular Dystrophy (OPMD) market size in revenue and volume.
Chapter 3: Detailed analysis of Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oculopharyngeal Muscular Dystrophy (OPMD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Oculopharyngeal Muscular Dystrophy (OPMD) capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Overall Market Size
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2022 VS 2029
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales: 2018-2029
3 Company Landscape
3.1 Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.2 Top Global Oculopharyngeal Muscular Dystrophy (OPMD) Companies Ranked by Revenue
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies
3.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies
3.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Oculopharyngeal Muscular Dystrophy (OPMD) Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.8.1 List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
3.8.2 List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Markets, 2022 & 2029
4.1.2 Tablets
4.1.3 Capsules
4.1.4 Injectable
4.1.5 Other
4.2 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
4.2.1 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2023
4.2.2 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2024-2029
4.2.3 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
4.3 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
4.3.1 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2023
4.3.2 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2024-2029
4.3.3 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
4.4 By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
5.2.1 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2023
5.2.2 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2024-2029
5.2.3 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
5.3 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
5.3.1 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2023
5.3.2 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2024-2029
5.3.3 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
5.4 By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2022 & 2029
6.2 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
6.2.1 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2023
6.2.2 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2024-2029
6.2.3 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
6.3 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
6.3.1 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2023
6.3.2 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2024-2029
6.3.3 By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029
6.4.2 By Country – North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2029
6.4.3 US Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.4.4 Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.4.5 Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029
6.5.2 By Country – Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2029
6.5.3 Germany Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.4 France Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.5 U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.6 Italy Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.7 Russia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.8 Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.5.9 Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029
6.6.2 By Region – Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2029
6.6.3 China Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.6.4 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.6.5 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.6.6 Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.6.7 India Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029
6.7.2 By Country – South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2029
6.7.3 Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.7.4 Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2018-2029
6.8.3 Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.8.4 Israel Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.8.5 Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
6.8.6 UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Benitec Biopharma Inc.
7.1.1 Benitec Biopharma Inc. Company Summary
7.1.2 Benitec Biopharma Inc. Business Overview
7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.1.5 Benitec Biopharma Inc. Key News & Latest Developments
7.2 Bioblast Pharma
7.2.1 Bioblast Pharma Company Summary
7.2.2 Bioblast Pharma Business Overview
7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.2.5 Bioblast Pharma Key News & Latest Developments
7.3 BioMarin
7.3.1 BioMarin Company Summary
7.3.2 BioMarin Business Overview
7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.3.5 BioMarin Key News & Latest Developments
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Company Summary
7.4.2 PTC Therapeutics Business Overview
7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.4.5 PTC Therapeutics Key News & Latest Developments
7.5 NS Pharma
7.5.1 NS Pharma Company Summary
7.5.2 NS Pharma Business Overview
7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.5.5 NS Pharma Key News & Latest Developments
7.6 Nobelpharma Co., Ltd
7.6.1 Nobelpharma Co., Ltd Company Summary
7.6.2 Nobelpharma Co., Ltd Business Overview
7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.6.5 Nobelpharma Co., Ltd Key News & Latest Developments
7.7 Santhera Pharmaceuticals
7.7.1 Santhera Pharmaceuticals Company Summary
7.7.2 Santhera Pharmaceuticals Business Overview
7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.7.5 Santhera Pharmaceuticals Key News & Latest Developments
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Company Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Inc. Key News & Latest Developments
7.9 Marathon Pharmaceuticals
7.9.1 Marathon Pharmaceuticals Company Summary
7.9.2 Marathon Pharmaceuticals Business Overview
7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.9.5 Marathon Pharmaceuticals Key News & Latest Developments
7.10 Fibrogen
7.10.1 Fibrogen Company Summary
7.10.2 Fibrogen Business Overview
7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.10.5 Fibrogen Key News & Latest Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Company Summary
7.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.11.5 Bristol-Myers Squibb Key News & Latest Developments
7.12 Sarepta Therapeutics
7.12.1 Sarepta Therapeutics Company Summary
7.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.12.5 Sarepta Therapeutics Key News & Latest Developments
7.13 GSK
7.13.1 GSK Company Summary
7.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2018-2023)
7.13.5 GSK Key News & Latest Developments
8 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, Analysis
8.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, 2018-2029
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity of Key Manufacturers in Global Market
8.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oculopharyngeal Muscular Dystrophy (OPMD) Supply Chain Analysis
10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Upstream Market
10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Oculopharyngeal Muscular Dystrophy (OPMD) in Global Market
Table 2. Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Companies, 2018-2023
Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies, (K Units), 2018-2023
Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
Table 9. List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2018-2023
Table 15. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2024-2029
Table 16. By Application – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2018-2023
Table 20. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2024-2029
Table 21. By Region – Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2018-2023
Table 25. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), 2024-2029
Table 26. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2018-2023
Table 29. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2024-2029
Table 30. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2018-2023
Table 33. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2024-2029
Table 34. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2018-2023
Table 37. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2024-2029
Table 38. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2018-2023
Table 41. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, (K Units), 2024-2029
Table 46. Benitec Biopharma Inc. Company Summary
Table 47. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 48. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Benitec Biopharma Inc. Key News & Latest Developments
Table 50. Bioblast Pharma Company Summary
Table 51. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 52. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Bioblast Pharma Key News & Latest Developments
Table 54. BioMarin Company Summary
Table 55. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 56. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. BioMarin Key News & Latest Developments
Table 58. PTC Therapeutics Company Summary
Table 59. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 60. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. PTC Therapeutics Key News & Latest Developments
Table 62. NS Pharma Company Summary
Table 63. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 64. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. NS Pharma Key News & Latest Developments
Table 66. Nobelpharma Co., Ltd Company Summary
Table 67. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 68. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Nobelpharma Co., Ltd Key News & Latest Developments
Table 70. Santhera Pharmaceuticals Company Summary
Table 71. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 72. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Santhera Pharmaceuticals Key News & Latest Developments
Table 74. Pfizer Inc. Company Summary
Table 75. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 76. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Pfizer Inc. Key News & Latest Developments
Table 78. Marathon Pharmaceuticals Company Summary
Table 79. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 80. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Marathon Pharmaceuticals Key News & Latest Developments
Table 82. Fibrogen Company Summary
Table 83. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 84. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Fibrogen Key News & Latest Developments
Table 86. Bristol-Myers Squibb Company Summary
Table 87. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 88. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Bristol-Myers Squibb Key News & Latest Developments
Table 90. Sarepta Therapeutics Company Summary
Table 91. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 92. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Sarepta Therapeutics Key News & Latest Developments
Table 94. GSK Company Summary
Table 95. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Offerings
Table 96. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. GSK Key News & Latest Developments
Table 98. Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 99. Global Oculopharyngeal Muscular Dystrophy (OPMD) Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2018-2023 (K Units)
Table 101. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region, 2024-2029 (K Units)
Table 102. Oculopharyngeal Muscular Dystrophy (OPMD) Market Opportunities & Trends in Global Market
Table 103. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers in Global Market
Table 104. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints in Global Market
Table 105. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials
Table 106. Oculopharyngeal Muscular Dystrophy (OPMD) Raw Materials Suppliers in Global Market
Table 107. Typical Oculopharyngeal Muscular Dystrophy (OPMD) Downstream
Table 108. Oculopharyngeal Muscular Dystrophy (OPMD) Downstream Clients in Global Market
Table 109. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Type in 2022
Figure 2. Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Application in 2022
Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2018-2029 (US$, Mn)
Figure 7. Oculopharyngeal Muscular Dystrophy (OPMD) Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Oculopharyngeal Muscular Dystrophy (OPMD) Revenue in 2022
Figure 9. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 11. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 12. By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 15. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 16. By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 20. By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 21. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 22. By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 23. US Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 28. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 29. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 37. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 41. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 43. By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 44. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2018-2029
Figure 48. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$, Mn), 2018-2029
Figure 52. Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Oculopharyngeal Muscular Dystrophy (OPMD) by Region, 2022 VS 2029
Figure 54. Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
Figure 55. Marketing Channels


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 眼咽頭型筋ジストロフィー（OPMD）の世界市場見通し2023年-2029年(Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 筋強直性ジストロフィー1型（DM1）の世界市場見通し2023年-2029年
  • 筋強直性ジストロフィー治療薬の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆